Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for ... headed by GLP-1RA treatments Wegovy (semaglutide) and Ozempic (semaglutide ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

The U.S. Food and Drug Administration is blocking sales of cheaper compounded versions of the drugs now that Wegovy and Zepbound ... have eaten into demand at some big companies, including Walmart ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

Novo Nordisk on Wednesday reported a better-than-expected rise in first-quarter net profit but lowered its full-year sales growth forecast as copycat drug compounders hit demand for its blockbuster ...